The 2013 testing guidelines for determining the human epidermal growth factor receptor 2 (HER2) status include new cutoff points for the HER2/chromosome enumeration probe 17 (CEP17) ratio and the average HER2 copy number per cell, and they recommend using a reflex test with alternative chromosome 17 probes (Ch17Ps) to resolve equivocal HER2 results. This study sought to determine the clinical utility of alternative Ch17Ps in equivocal cases and the effects of equivocal results and/or a change in the HER2 status on patients' outcomes. METHODS: The University of Texas MD Anderson Cancer Center database of HER2 dualprobe fluorescence in situ hybridization results from 2000 to 2010 was searched for cases of invasive breast cancer with HER2/ CEP17 ratios < 2 and average HER2 copy numbers < 6 per cell. Cases with HER2 copy numbers of 4 to < 6 (the definition of equivocal HER2 results) were analyzed with alternative Ch17Ps for Smith-Magenis syndrome and retinoic acid receptor a genes. Disease-free survival (DFS) and overall survival (OS) were evaluated with respect to the HER2 copy number with multivariate Cox proportional hazards regression. RESULTS: Among the 3630 patients meeting the inclusion criteria, 137 (4%) had equivocal HER2 results. With alternative Ch17Ps, 35 of 57 equivocal HER2 cases (61%) were upgraded to a positive HER2 status, and 22 cases (39%) remained unchanged. The 5-year DFS and OS adjusted hazard ratios (HRs) for copy numbers of 4 to < 6 versus < 4 were 0.6 (95% confidence interval [CI], 0.3-1.2) and 0.5 (95% CI, 0.2-1.0) with P values of .16 and .66, respectively. In comparison with HER2-negative cases, these CIs indicated that equivocal HER2 results were associated with either a protective effect (HR, < 0.5) or no effect (HR, 1.0). CON-CLUSIONS: These findings rule out a significant deleterious effect of equivocal HER2 results. Alternative Ch17Ps may erroneously upgrade the HER2 status; therefore, they cannot be considered reliable in clinical practice. Cancer 2017;123:1115-23.
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth factor receptor family, is encoded by a gene (HER2 or ERBB2) located on the long arm of chromosome 17 (17q12). HER2 amplification, overexpression, or both are noted in approximately 15% to 20% of invasive breast cancers 1 and are associated with a poor prognosis. Most importantly, breast cancers with HER2 overexpression or gene amplification can be targeted with agents that are remarkably effective in both metastatic and adjuvant settings. 1 Because the HER2 status predicts whether HER2-targeting agents would provide a benefit, a precise assessment is essential for treatment decisions. 2 Two diagnostic techniques, immunohistochemistry (IHC) and in situ hybridization (ISH), are currently approved for assessing the HER2 status in clinical practice. 3 Fluorescence in situ hybridization (FISH) is the most commonly used ISH technique. FISH is conducted with either a single probe to enumerate HER2 copies per nucleus or dual probes-a HER2 probe and a chromosome 17 centromere probe (chromosome enumeration probe 17 [CEP17])-to allow determination of the HER2/CEP17 ratio. The HER2/CEP17 ratio has long been regarded as a better reflection of the HER2 gene status than the mean HER2 copy number because it compensates for the loss of signals by tissue sectioning and adjusts for the natural increase in the number of chromosomes during replication. 4 In 2007, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) developed guidelines for HER2 testing in breast cancer and advocated that results be reported as positive, negative, or equivocal. 2 Equivocal HER2 results have been attributed to chromosome 17 polysomy because the number of CEP17 signals in tumor nuclei has been generally considered a surrogate of the number of copies of chromosome 17 .
Recent studies, however, have shown that true polysomy 17 is extremely rare in breast cancer and that an increased CEP17 copy number often results from amplification or copy number gain in the centromeric or pericentromeric region. [4] [5] [6] [7] [8] [9] [10] [11] [12] Consequently, in 2013, ASCO/CAP released new guidelines for HER2 testing that included cutoff points differing from those in the 2007 guidelines for the ISH HER2/CEP17 ratio and the average HER2 copy number per cell; the guidelines also recommend the use of a reflex test with alternative chromosome 17 probes (Ch17Ps) for resolving equivocal HER2 ISH results. 13 FISH probes that have been used as surrogates for chromosome 17 in cases with a high CEP17 copy number have included Smith-Magenis syndrome (SMS; also called RAI1), retinoic acid receptor a (RARA), and TP53. 5, 11, 12 The SMS probe targets sequences at 17p11.2, and the RARA probe hybridizes with RARA and neighboring genes at 17q21.2. Although some studies 4, 5, 13 have advocated the use of these alternative chromosome 17 genes as surrogates, others 7, 12 have cautioned against their use in daily practice because of frequent heterozygous deletions. Furthermore, the clinical utility of these tests with respect to the clinical course of disease has not been determined.
Although the goal of the new ASCO/CAP guidelines is to ensure maximal accuracy of HER2 testing, the numbers of equivocal cases have been noted to increase in a significant number of cases. 12, 14 The increase in the number of equivocal cases, compounded by the lack of a uniform approach to resolving such problems, makes treatment recommendations for this group of patients difficult. We, therefore, undertook this study to determine the relation between an equivocal HER2 copy number (4 to < 6) and patients' outcomes. We also determined whether equivocal HER2 results could be resolved with alternative chromosome 17 genes (RARA and SMS) and whether a change in the HER2 status based on the use of alternative Ch17Ps was associated with patients' outcomes.
MATERIALS AND METHODS

Patient Population
This study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center. Our institution's database of HER2 dual-probe FISH results was searched for cases of invasive breast cancer. For the period between 2000 and 2010, there were 7862 patients with invasive breast cancer and clinical and pathological data available for analysis. Of these, 5157 had a HER2 assay within 6 months of their diagnosis. Of these, 3651 had stage I to III disease, were not treated with trastuzumab, and had a HER2/CEP17 ratio < 2. Of these, 3630 had complete disease-free survival (DFS) and overall survival (OS) data and a minimum of 5 years' follow-up. Of these, 3493 (96%) had a HER2 copy number of < 4 signals per cell, and 137 (4%) had a HER2 copy number between 4 and <6 signals per cell (cases meeting the new ASCO/CAP definition of equivocal).
Sixty-three of the 137 cases with equivocal HER2 results had tissue sections available for additional testing of the alternative SMS/RARA genes.
FISH
HER2/CEP17 analyses were performed with the Vysis PathVysion probe kit, which includes a SpectrumGreenconjugated probe for the a-satellite DNA located in the centromeric region of chromosome 17 (17p11.1-q11.1) and a SpectrumOrange-conjugated probe for the HER2 gene locus (Abbott Molecular/Abbott Laboratories, Abbott Park, Ill). Briefly, 4-mm paraffin sections were deparaffinized and hybridized according to the manufacturer's instructions. Fluorescence was visualized with an Olympus microscope with multiple filters and was correlated directly with hematoxylin-eosin-stained tissue sections to ensure scoring of invasive carcinoma. HER2 and CEP17 signals were manually counted in 60 tumor cells, and a total HER2/CEP17 ratio was calculated.
Corresponding tissue sections (available in 63 cases) were analyzed for SMS and RARA gene copy numbers with Vysis probe sets (Abbott Molecular/Abbott Laboratories) for the SMS critical region at 17p11.2 (encompassing genes SHMT1, TOP3A, FLII, and LLGL1 and labeled with SpectrumOrange) and RARA at 17q21.2 (encompassing GRB7, MLN51, SHGC-146999, THRA, and RARA exons 2-6 and labeled with SpectrumGreen). The FISH procedure was performed according to the manufacturer's instructions. Manual counting was performed Original Article on all samples. Gene signals per cell in 20 tumor nuclei were evaluated for each case. The criteria used to calculate a revised HER2/chromosome 17 ratio were the same as those used previously. 4, 12 Briefly, if any of the SMS or RARA signals were found to be less than 2.6 per cell, the gene with the highest signal count was chosen as the chromosome 17 reference gene instead of CEP17 for the calculation of the HER2 ratio. Cases displaying < 1.5 signals per cell were considered to be hypodisomic. The revised HER2 status based on the HER2/Ch17P ratio was stratified as positive or unchanged.
Statistical Analysis
DFS and OS were computed from the date of diagnosis to the first event. DFS and OS of patients with HER2 copy numbers of < 4 versus 4 to < 6 were estimated with Kaplan-Meier curves. Hazard ratios (HRs) were estimated with Cox proportional hazards regression models. These results were then adjusted for the following variables: age (<40, 40-49, 50-59, or 60 years), race (white vs other), menopausal status (before vs after), nodal status (negative vs positive), tumor grade (well, moderately, or poorly differentiated), tumor type (ductal, lobular, tubular, mucinous, or other), pathological tumor size (>2 vs < 2 cm), and estrogen/progesterone receptor status (positive vs negative). The proportional hazards assumptions of the Cox models were verified with a rescaled Schoenfeld residual analysis.
DFS and OS of the patients with equivocal HER2 results were also calculated on the basis of the revised HER2 ratio obtained after the use of alternative probes.
The immunohistochemical score distribution of HER2 protein expression (31, 21, 11, or 0) was compared for patients with and without a change from an equivocal HER2 status to a positive HER2 status with an exact Wilcoxon rank-sum test.
RESULTS
Clinical Outcomes
In all, there were 7862 patients with invasive breast cancer and available clinical and pathological data for analysis, and 3630 met our inclusion criteria and had a HER2/CEP17 ratio < 2 and an average HER2 copy number < 6 signals per cell. Of these, 137 (4%) had a HER2 copy number between 4 and <6 signals per cell (equivocal results), and 3493 (96%) had a HER2 copy number of < 4 signals per cell. All 137 cases with HER2-equivocal results had a CEP17 copy number gain (range, 2.4-8.9 signals per cell), with the majority of cases (131 of 137) having an average CEP17 copy number per nucleus > 2.6.
Kaplan-Meier DFS and OS curves stratified by the HER2 copy number (4 to < 6 vs < 4 signals per cell) are shown in Figures 1 and 2 , respectively. Further analysis of this phenomenon using multivariate Cox proportional hazards regression models, which were adjusted for age, race, menopausal status, number of positive lymph nodes, tumor histological type and grade, tumor size, and hormone receptor status (2864 patients in all with complete data), showed that the 5-year DFS for patients with a HER2 copy number of 4 to < 6 signals per cell did not significantly differ from that for patients with a copy number of <4 signals per cell (HR, 0.6; 95% CI, 0.3-1.2; P 5 .16); the same was true for 5-year OS (HR, 0.5; 95% CI, 0.2-1.0; P 5 .66). In comparison with HER2-negative cases, both of these CIs indicate that the equivocal HER2 copy number (4 to < 6) is associated with either a protective effect (HR, < 0.5) or no effect (HR, 1.0). Importantly, these findings rule out a significant deleterious effect of an elevated HER2 copy number in the absence of targeted therapy.
FISH Results Using SMS and RARA Probes
Of the 137 equivocal cases scored on the basis of HER2/ CEP17 ratios < 2 and mean HER2 copy numbers of 4 to < 6, 63 had tissue available for analyses. Six of the 63 cases were excluded because residual invasive cancer was absent in the sections. The results of the average copy number of HER2, CEP17, and alternative Ch17 genes (SMS and RARA) per nucleus and the revised HER2 ratio are shown in Table 1 . Of the 57 cases, 35 (61%) had their HER2 gene status upgraded from equivocal to positive (Fig. 3) , and the remaining 22 cases (39%) remained unchanged. The distribution of the FISH results on chromosome 17 for the 57 patients is shown in Figure 4 .
Kaplan-Meier DFS and OS curves stratified by the ratio of HER2 to alternative chromosome 17 genes are shown in Figures 5 and 6 . Both the DFS results and the OS results were inconclusive. The 95% confidence intervals for the HRs include values < 0.5, which indicate a significant protective effect for elevated ratios, and values > 2.0, which indicate a significant deleterious effect for elevated ratios. Because the data are consistent with both of these hypotheses (protective and deleterious effects for elevated ratios), we must conclude that the data are inconclusive rather than negative on account of the small numbers of patients included.
We compared the FISH results for the 57 cases before and after the use of alternative Ch17Ps with HER2 protein overexpression by IHC. Forty-six of these 57 cases had available IHC data (Table 1) . Of the 46 cases, 43.5% showed 2 1 HER2 protein expression (equivocal results), and 47.8% were negative (11). Only 2 cases were positive (31) , and these cases remained equivocal/unchanged with the use of SMS/RARA genes. No correlation was found between the distribution of IHC scores and HER2 FISH results before and after the use of alternative Ch17Ps (P 5 .24; Table 2 ).
DISCUSSION
In our study, equivocal HER2 results approached 4% of the total cases with HER2/CEP17 ratios < 2. This rate is similar to those reported by others. 12, 14 In comparison with HER2-negative cases, we have demonstrated that HER2-equivocal results (ie, HER2 copy number, 4 to < 6) in the absence of trastuzumab-based therapy have no deleterious effects on patient outcomes. In addition, we have demonstrated that the revised HER2 status due to the use of alternative Ch17 probes is not reflective of patient outcomes.
The impact of equivocal HER2 results on patient outcomes has not been fully evaluated. Most published reports have dealt with CEP17/so-called polysomy 17, and the results were rarely in direct relation with the increase in HER2 copy numbers. Because equivocal HER2 results by ISH are often associated with an increased CEP17 copy number, a review of clinical studies focusing on elevated CEP17/polysomy 17 is relevant and may reflect the impact of equivocal HER2 results. An elevated CEP17 count (CEP17 > 3 signals per cell) was reported to be associated with higher nuclear and histological grades and estrogen receptor negativity, 15 a high proliferative rate, 16 and nodal involvement 17 in comparison with nonpolysomic tumors; however, other studies [18] [19] [20] [21] found no significant differences between tumors with a CEP17 copy number 3 and tumors with a CEP17 copy number < 3 in clinicopathological variables.
Studies that have directly focused on HER2 gene amplification or copy numbers or on HER2 protein expression have demonstrated that intermediate HER2 amplification/low-level gene copy numbers or protein expression influences breast cancer behavior. 18, [22] [23] [24] In one study of 1400 breast cancer cases with more than 15 years of follow-up, 22 the authors reported that cases with intermediate HER2 ratios between 1.5 and 2.2 (which are often a reflection of a slight increase in the HER2 copy number) had a significantly better outcome than the conventional amplified group (HER2 ratio > 2.2) and a significantly worse outcome than cases with FISH ratios less than 1.5. In the study by Vanden Bempt et al, 18 an equivocal HER2 gene status, in contrast to HER2 gene amplification, was not associated with reduced DFS, although survival was intermediate between the survival of HER2-negative and HER2-positive patients. Similarly, in our study, the DFS and OS adjusted HRs for patients with HER2 copy numbers of 4 to < 6 versus < 4 were 0.6 (P 5 .16) and 0.5 (P 5 .66), respectively, and this indicates that an elevated HER2 copy number is not associated with a significant deleterious effect on patient outcomes (in the absence of adjuvant or neoadjuvant trastuzumab). Conversely, in another study of 91 nodepositive patients with invasive breast carcinoma treated Original Article with mastectomy and doxorubicin-based chemotherapy without trastuzumab with a median follow-up of 12.5 years, the authors found that even a low level of HER2 expression (1 1 with IHC) in the primary tumor was significantly associated with decreased locoregional recurrence-free survival, DFS, and OS. 23 Despite the recent findings that true polysomy 17 in breast cancer is rare and that an increased CEP17 copy number often results from amplification or copy number gain in the centromeric or pericentromeric region, 4, 6, 7, 9, 10 the 2013 ASCO/CAP guidelines advocate additional testing in equivocal cases. 13 This can be done via testing for additional genes on chromosome 17 that are not expected to co-amplify with HER2. 13, 25 The selective use of alternative Ch17Ps for RARA, SMS, and TP53 genes in some studies was due to their commercial availability and ease of testing in the clinical setting. In our study, the use of SMS and RARA genes resulted in a change in the HER2 status from equivocal to positive in 61% of patients with HER2 copy numbers of 4 to < 6. These findings are concordant with those reported previously. 4, 5, 12 In a study by Tse et al 4 using 3 different chromosome 17 genes (SMS, RARA, and TP53), 48% of the cases (41 of 86) with a mean HER2 copy number of 4 to 6 and increased CEP17 signals had their HER2 gene status upgraded from unamplified to amplified/positive. In another study, Jang et al 12 reported that more than 75% of cases with an equivocal HER2 status were upgraded to an amplified status after additional FISH analyses for the same 3 probes. In these studies, however, no clinical outcome data were available. Although our results with respect to the change in the HER2 status due to the use of alternative Ch17Ps are similar to those reported previously, the criteria used in the Table 1 ). Increased signals are shown for the RARA gene (average copy number per nucleus, 5; green signals), whereas the SMS gene shows a disomic signal (average copy number per nucleus, 1.5; red signals). According to previously published criteria, these findings resulted in a change in the human epidermal growth factor receptor 2 status from equivocal to positive (see the Discussion section for further comments). RARA indicates retinoic acid receptor a; SMS, Smith-Magenis syndrome. Table 1 ). Note: One case showed monosomy of both SMS and RARA genes and was excluded from this illustration. CEP17 indicates chromosome enumeration probe 17; HER2, human epidermal growth factor receptor 2; RARA, retinoic acid receptor a; SMS, Smith-Magenis syndrome. interpretation of the published data are questionable. Recent studies have demonstrated the presence of frequent complex structural alterations of chromosome 17 in breast cancer cases, including losses and gains of genetic material in both the long and short arms as well as gains and losses of centromeric regions, 6, 7, 26 and they have proven that the use of additional FISH probes such as SMS and RARA are not sufficient for correcting the HER2 gene status. 7, 12 Furthermore, in a comprehensive review, Jang et al 12 highlighted many of the limitations associated with these genes. For example, the RARA gene, which is located at 17q21, maps very closely to HER2 and is amplified in up to 51% of HER2-amplified breast cancers. On the other hand, the SMS gene, which is located at 17p11.2, is rarely amplified or co-amplified; however, its loss is frequently identified because of heterozygous deletions. Although TP53, which is located at 17p13.1, is relatively far from HER2, it is one of the most frequently mutated genes in breast cancer. 12 As advocated by Jang et al, the use of more stable genes could be considered; however, on the basis of data from The Cancer Genome Atlas, at least a quarter had a copy number deletion, and as a result, their use may be limited as alternative reference genes for chromosome 17. In our study, the finding that these patients had outcomes that were no worse than those of the HER2-negative cases, as would not be expected for a cohort containing a substantial number (61%) of upgraded cases (HER2-positive), coupled with the lack of associations with HER2 overexpression (IHC31) among the upgraded HER-2 positive cases, indicates that these alternative Ch17 genes may lead to overestimations of HER2-positive cases because of an unrecognized reduction in the signal number due to heterozygous deletions and thus lead to erroneous upgrading of the HER2 status to positive.
Whether this new category of patients with equivocal HER2 results upgraded to a HER2-positive status will have more aggressive disease or will have a favorable response to targeted therapy has not been fully determined. Previous studies, however, have indicated that tumors with extra copies of HER2 (which used to be attributed to polysomy 17) represent a distinct group of cases and are fundamentally different from tumors with extra copies resulting from HER2 gene amplification. 19, 27, 28 For example, in contrast to what occurs with gene amplification, these cases are not associated with increased HER2 messenger RNA and do not overexpress protein at the significant IHC 3 1 level. Only 2 of our 46 cases showed 3 1 protein overexpression, and the remaining cases were distributed among 1 1 and 2 1 protein expression, regardless of the changes in the HER2 gene status resulting from the use of alternative Ch17Ps (P 5 .24). Furthermore, the treatment response to targeted therapy may Figure 6 . Kaplan-Meier OS curves according to the HER2/alternative chromosome 17 gene ratio in 57 patients with equivocal HER2 results (22 with ratios < 2 and 35 with ratios 2). CI indicates confidence interval; HER2, human epidermal growth factor receptor 2; OS, overall survival. vary with the HER2 copy numbers or the HER2/CEP17 ratio. [29] [30] [31] [32] [33] In one study, the pathological complete response rate for trastuzumab-based neoadjuvant therapy was significantly higher for high-amplification tumors (defined as > 10 signals per nucleus) versus lowamplification tumors (defined as 6-10 signals per nucleus; 56% vs 22%; P 5 .005). 29 Other studies have shown that a high HER2/CEP17 ratio is a significant predictor of progression-free survival 30 in patients with metastatic breast cancer treated with chemotherapy and trastuzumab, and a ratio 7.0 was also a predictor of a pathological complete response in patients with locally advanced breast cancer who received neoadjuvant chemotherapy and trastuzumab. 31 However, in National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, no significant association between the HER2 copy number and a benefit from adjuvant trastuzumab was found, and even patients with normal gene copy numbers appeared to benefit from trastuzumab. 32 In a subsequent analysis, 33 using a gene expression profile, the authors developed a model that could predict the degree of benefit from trastuzumab and also demonstrated that that patients with HER2-negative tumors belong to the moderate-benefit group. This finding is being tested through a randomized clinical trial (NSABP protocol B-47). 33 Future clinical trials should be extended to cases with equivocal HER2 results to determine the degree of benefit of HER2 targeted therapy in a fashion similar to that of HER2-negative cases.
In summary, considering the extremely low incidence of true chromosome 17 polysomy, the lack of consensus on the use of alternative genes, and our clinical data (though from a limited sample size) showing that tumors with equivocal HER2 results more closely resemble HER2-negative cases than conventional HER2-amplified cases, we believe that the use of alternative chromosome 17 genes in determining the HER2 status is of limited value and perhaps not needed and that the management of patients with equivocal HER2 results (HER2 copy number, 4 to < 6) should not rely on the use of alternative Ch17P testing.
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